Showing results (191-200 of 374) with videos related to
Sort By:
Pageof 38
Cancer Research|October 15, 1991
Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomasD S Hoon, E Okun, M Banez, et al.Journal of Clinical & Laboratory Immunology|August 1, 1990
Differential effects of granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor on tumor necrosis factor and interleukin-1 production in human monocytesR Essner, K Rhoades, W H McBride, et al.Annals of Surgical Oncology|June 23, 2000
TA90-IC, a new marker for advanced colon cancerN Habal, R K Gupta, A J Bilchik, et al.Journal of the National Cancer Institute|May 1, 1982
Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell populationS H Golub, F Dorey, D Hara, et al.The Journal of Investigative Dermatology|February 16, 1999
IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patientsT Takahashi, T D Johnson, Y Nishinaka, et al.Annals of Surgical Oncology|November 27, 1998
Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survivalE C Hsueh, E Famatiga, R K Gupta, et al.The Journal of Urology|December 1, 1993
Aberrant expression of gangliosides in human renal cell carcinomasD S Hoon, E Okun, H Neuwirth, et al.Cancer Immunology, Immunotherapy : CII|November 1, 1993
Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cellsD S Hoon, Y Hayashi, T Morisaki, et al.Cancer|January 1, 1976
Regional lymph node metastases and the level of invasion of primary melanomaE C Holmes, W Clark, D L Morton, et al.Cancer Treatment Reports|November 1, 1979
Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanomaJ E Goodnight, H S Moseley, F R Eilber, et al.Pageof 38